Rett's Angels girls beat bad weather

Eight families from across Kent braved snow and ice to take part in Lorraine Hockey's fifth annual Christmas Party for Rett's Angels.
It is held for girls suffering from Rett Syndrome which makes them unable to walk or talk.
Lorraine's own daughter Cassie, 17, suffers from the illness.

Mum-of-two Lorraine, 53, who lives in Hodgson Road, Seasalter, and runs Jaguar Carpets in Herne Bay with her husband Keith, said: "Our volunteer harpist could not make it because of bad weather and I was worried nobody would show on Saturday.
"But eight families did. They came from as far as Bexleyheath, Deal and Maidstone.
"Ironically, Seasalter remained remarkably untouched by the bad weather although I had hired a snow machine specially!"

The gathering is usually held at Whitstable's Horsebridge Centre but switched to the Seasalter Christian Centre to save costs.

The event was helped by donations from Ward and Partners, the Co-operative Society and the Whitstable Carnival Committee. Entertainment was provided by jugglers from Kent Circus School.
A specially-edited DVD of the parties is to be launched in the new year to show sponsors where their money goes and to attract new supporters.
Rett's Angels has already been adopted by women members of Herne Bay Golf Club as its charity of the year. It provides support for sufferers and their families.

Rett Syndrome is a neurological disease which affects one in 10,000 children, usually girls, which has led to the name Rett's Angels. Sufferers lose the ability to walk and talk and have to be cared for as if they are babies.

Source: thisiskent.co.uk

Rett symptoms stem from gene loss in cells that make specific neurotransmitters

Read the article

Vote for Rett syndrome

Rett Syndrome most disabling of all the autistic disorders

Read the letter

Strong evidence for significant longevity of Rett syndrome patients

Read the article.

October is Rett Syndrome Awareness month

Rett Syndrome Astrocytes Are Abnormal and Spread MeCP2 Deficiency through Gap Junctions

MECP2, an X-linked gene encoding the epigenetic factor methyl-CpG-binding protein-2, is mutated in Rett syndrome (RTT) and aberrantly expressed in autism. Most children affected by RTT are heterozygous Mecp2–/+ females whose brain function is impaired postnatally due to MeCP2 deficiency. While prior functional investigations of MeCP2 have focused exclusively on neurons and have concluded the absence of MeCP2 in astrocytes, here we report that astrocytes express MeCP2, and MeCP2 deficiency in astrocytes causes significant abnormalities in BDNF regulation, cytokine production, and neuronal dendritic induction, effects that may contribute to abnormal neurodevelopment. In addition, we show that the MeCP2 deficiency state can progressively spread at least in part via gap junction communications between mosaic Mecp2–/+ astrocytes in a novel non-cell-autonomous mechanism. This mechanism may lead to the pronounced loss of MeCP2 observed selectively in astrocytes in mouse Mecp2–/+ brain, which is coincident with phenotypic regression characteristic of RTT. Our results suggest that astrocytes are viable therapeutic targets for RTT and perhaps regressive forms of autism.

Source: The Journal Of Neuroscience

New insight into Rett syndrome severity

A research collaboration between Australia and Israel has identified a genetic variation that influences the severity of symptoms in Rett syndrome.
The finding is published in the latest edition of the international journal Neurology.

Dr Helen Leonard, who heads the Australian Rett Syndrome Study at the Telethon Institute for Child Health Research, said the finding was exciting in that it identifies a potential new target for treatment of the debilitating neurological disorder.
"We know that there is a wide range in the onset and severity of symptoms in patients with Rett syndrome but it has been difficult to give families a firm idea of how the disorder would progress," Dr Leonard said.
"This information is potentially helpful in predicting the clinical progression, but importantly, gives us another area to explore for potential therapies."

In the study, clinical information and DNA samples were gathered from 125 patients from the Australian Rett Syndrome Database and an Israeli cohort coordinated by Dr Bruria Ben Zeev at the Safra Pediatric Hospital, Sheba Medical Centre, Sackler School of Medicine, Tel Aviv. The genetic testing was undertaken by Professor John Christodoulou, from the NSW Centre for Rett Syndrome Research at the Children's Hospital at Westmead in Sydney and Dr Eva Gak from the Sagol Neuroscience Center at the Sheba Medical Centre.
Professor Christodoulou said while it has been established that Rett syndrome is caused by mutations in the MECP2 gene, these new findings have established a correlation between the severity of clinical symptoms and a common brain-derived neurotrophic factor (BDNF) polymorphism.

"Those patients with the normal BDNF genetic variant had less severe symptoms, with later onset and frequency of seizures," Dr Christodoulou said.
"We know that BDNF plays a major role in the development, survival and function of brain cells. What we now have to establish is the nature of the interaction between MECP2 and BDNF."
"It may be that if we can stimulate BDNF within patients with Rett syndrome, there is a chance that we can delay the onset of seizures and reduce some of the more debilitating aspects of the disorder."

View source

Rett gene in amygdala linked to fear and learning

Deleting the gene associated with Rett syndrome from the amygdala region of mouse brains triggers anxiety and problems with learning and memory, according to research published today in the Journal of Neuroscience 1.

Researchers at the University of Texas Southwestern Medical Center at Dallas selectively deleted the MeCP2 gene, mutations in which cause Rett syndrome, from the amygdala — a clustering of cells in the brain that regulates the processing of emotions — of 3- to 5-month-old mice.

These mice, which express roughly 50 percent of normal MeCP2 levels in the amygdala, freeze when placed in a maze task routinely used to assess anxiety, the researchers found. The mice also have trouble remembering to anticipate a brief shock after an auditory tone — a task that control mice learn and remember after two tries — suggesting that MeCP2 regulates fear-dependent learning and memory.

Rett syndrome is a rare neurodevelopmental disorder that predominantly affects girls, and is characterized by distinctive hand movements, abnormal gait, seizures and mental retardation. Girls with the syndrome also often show features of autism, including anxiety, deficits in social skills and repetitive behavior.

Intriguingly, mice lacking MeCP2 in the amygdala show normal patterns of social interaction. “We were sort of surprised because it does suggest you can separate out anxiety from social interaction deficits,” says lead investigator Lisa Monteggia.

“For autism spectrum disorder, one of the most debilitating aspects is the social deficit,” Monteggia says. “So if we go back to other brain regions, could we recapitulate the social interaction deficits?”

A research team led by Huda Zoghbi in 1999 first linked mutations in the MeCP2 gene to Rett syndrome2, but the gene’s exact role is still unknown. Last year, the same group reported that the gene is a master regulator, controlling the activation and repression of thousands of other genes3.

Because MeCP2 is found throughout the body, it has been difficult to tease apart its contribution to the collection of symptoms seen in Rett syndrome. For example, mice that don’t have any MeCP2 are normal until 5 weeks of age, when they begin to develop Rett-like symptoms, and then die between 6 and 12 weeks of age4.

“When this protein is missing everywhere in the brain, the animals are so sick that you may miss hidden phenotypes,” Zoghbi says. “By looking at the gene just in specific areas, you might be able to learn the symptoms emanating from those specific brain regions.”

Regional deletions:
In 2001, Rudolf Jaenisch and colleagues created mice that lack the gene in the forebrain, a large region of the brain that includes the amygdala and performs a gamut of functions from sensory processing to memory, beginning at postnatal day 14, when neuronal connections are actively forming.

Monteggia’s group showed in 2006 that these mice have a broad array of Rett-like symptoms, including anxiety, learning and memory problems, deficits in motor coordination and social deficits5. The researchers then decided to focus specifically on the amygdala because anxiety, learning and memory tasks are regulated by the region.

Because some of Rett’s symptoms, including difficulty breathing and sleeping and elevated response to stress, implicate the hypothalamus, Zoghbi and her colleagues in September 2008 selectively deleted MeCP2 from the mouse hypothalamus and found that the mice are more aggressive and tend to eat more than do control littermates6.

In the new study, Monteggia and her colleagues also exposed normal mice to a histone deacetylase inhibitor — a chemical that enhances gene expression — and found that these normal mice and the MeCP2-deficient mice show similar behavioral deficits.

“To us, it suggested that these behavioral processes that we think MeCP2 is involved in were mediated through transcriptional repression,” Monteggia says.

Deletions from specific brain regions allow researchers to dissociate different brain functions that might involve different brain regions, says Mriganka Sur, chief of brain and cognitive sciences at the Massachusetts Institute of Technology. Still, to treat Rett syndrome, it will be important to intervene broadly in the brain, he notes.

Sur and his colleagues have found that treating mice that lack MeCP2 throughout the brain with insulin-like growth factor 1, a chemical that improves cell survival and maturation, improves the lifespan and locomotor activity7. The growth factor also strengthens connections between neurons, which is likely to be relevant to MeCP2’s role in regions like the amygdala.

“To my mind [the new study] argues that the MeCP2 gene is really involved in the kind of function that we postulated,” says Sur, “that MeCP2 is involved in synaptic maturation and regulating plasticity.”

View source

European Rett Syndrome Congress, June 5-7, Milan, Italy

1st European Congress on Rett Syndrome - Università degli Studi di Milano, June 5-7, 2009

Rett Syndrome is a rare disease which springs from a genetic mutation of a specific gene, the MECP2, and provokes severe problems to the "girls with beautiful eyes", including neurological disfunctions in movement and development of the brain, cardiac problems, gastric disfunctions and many others.

We need your help to substain AIR (Associazione Italiana Sindrome di Rett) and RSE (Rett Syndrome Europe) and divulgate the results of recent researches on the disease.
Please help us make Rett Syndrome a studied and well-known disease, registering to the congress and bringing your contribution through submittance of an abstract through the web site www.aimgroup.it/29009/airett.

AIR
RSE
The Organizing Secretariat

Click here to download the files.

Rett gene plays crucial role in glia

Study says Rett gene's role in glia, not neurons, crucial to syndrome

MECP2, the gene that causes the autism-related Rett syndrome, is expressed not just in neurons but in glia — cells that support neurons and help process information — in the brain, according to a study published online in the March issue of Nature Neuroscience 1.

What’s more, it’s MeCP2’s loss from these glia, and not from neurons, that appears to be important in causing the disorder. Glia make up roughly 90 percent of cells in the nervous system, and are thought to be crucial for the survival and maturation of neurons.

Rett syndrome is a rare neuro-developmental disorder that affects girls within the first 18 months of life. Beginning with delayed growth and speech, the disorder progresses and, as a result of severe impairments in motor function, often leaves girls wheelchair-bound by their early 20s.

A decade ago, Huda Zoghbi and her team first linked mutations in MeCP2 to the disorder2. Mutations in the same gene, which has been found to activate and repress thousands of other genes, are also found in people with learning disabilities, mental retardation and autism.

Several studies of Rett syndrome had reported MeCP2’s presence in neurons, but not in glia3. But a few years ago, some researchers began looking closer at the gene’s expression in glia because it is present in many other non-neuronal cell types — such as fibroblasts and muscle cells — outside the brain, says Nurit Ballas.

Ballas, who conducted the work as a research associate in the lab of Gail Mandel, is now associate professor of chemistry and cell biology at Stony Brook University in New York.

“I thought, ‘Why would I not see [MeCP2] in glia?’” Ballas recalls. She decided to use a sensitive antibody and a new way of staining for the protein that could enhance the signal.

Diverse locations:
She and her colleagues found that MeCP2 is present in all types of healthy mouse glia, including astrocytes — star-shaped cells that help regulate a neuron’s chemical environment — and oligodendrocytes, which form a protective sheath over neurons. In contrast, the protein is not detectable in the glia of mouse models of Rett syndrome.

Neurons cultured on a bed of astrocytes taken from Rett mice also have fewer and shorter dendrites — the long fibers of neurons that receive signals — compared with neurons cultured on healthy astrocytes.

Conversely, adding healthy astrocytes to neurons that lack MeCP2 restores the growth of dendrites in those neurons.

“To me the biggest surprise came from the fact that an astrocyte that doesn’t have this protein is compromised in its capacity to support neurons,” says Zoghbi, a Howard Hughes Medical Institute Investigator at the Baylor College of Medicine in Houston.

Even the astrocyte-conditioned medium — a nutrient broth secreted by astrocytes that can normally support neuron growth in culture — from the Rett mice stunts proper development of neurons.

The researchers are trying to selectively eliminate MeCP2 from mouse astrocytes and other glia in order to determine the relative roles of these cells in triggering Rett syndrome.

“We also want to know what the factors are in the media that astrocytes are secreting, and whether that plays a role in Rett,” Mandel says.

Because MeCP2 normally controls the expression of many genes, the lack of a functional MeCP2 in these astrocytes could stunt the neurons’ growth by somehow altering the chemical milieu in a neuron’s environment, the authors note.

“If it is true that the astrocytes are secreting a toxic inhibitory factor,” Mandel adds, “then that’s a point of potential pharmaceutical intervention.”


Zie http://sfari.org/news/study-says-rett-gene-s-role-in-glia-not-neurons-crucial-to-syndrome

A possible treatment for Rett syndrome

Study suggests molecule can reverse some symptoms
CAMBRIDGE, Mass.— A molecule that promotes brain development could serve as a possible treatment for Rett syndrome, the most common form of autism in girls, according to researchers at MIT's Picower Institute for Learning and Memory and the Whitehead Institute for Biomedical Research.
The researchers found that injecting the molecule into mice that have an equivalent of Rett syndrome helped the animals' faulty brain cells develop normally and reversed some of the disorder's symptoms.
The work, reported in the Feb. 10 online edition of the Proceedings of the National Academy of Sciences (PNAS), is expected to lead to new human clinical trials for a derivative of growth factor-1 (IGF-1), currently used to treat growth disorders and control blood glucose. The MIT study indicates that IGF-1 could potentially lessen the severity of symptoms of Rett syndrome.
"We demonstrate that a major underlying mechanism behind Rett syndrome in mice is that synapses in the brain remain immature and show persistent, abnormal plasticity into adulthood," said Daniela Tropea, a postdoctoral fellow at the Picower Institute and lead author of the study. "We also propose that a therapeutic based on this mechanism would be directly applicable to humans."
Injecting mice with a peptide fragment of IGF-1, used by the brain for neuronal and synaptic development, reverses a large number of symptoms of mice genetically engineered to display Rett syndrome-like symptoms.
"IGF-1 is critical for brain development. It activates molecules within neurons that make synapses mature," said study co-author Mriganka Sur, the Newton Professor of Neuroscience at the Picower Institute and head of the MIT Department of Brain and Cognitive Sciences. "This is a mechanism-based therapeutic for Rett syndrome. It is possible that this or similar therapeutics would apply to other forms of autism, which also have as their basis a persistent immaturity of synapses."
HELPING NERVE CELLS MATURE
Rett syndrome, an inherited neurological disorder, causes loss of speech, reduced head size, breathing and heart abnormalities and autism-like symptoms in one out of 10,000 girls.
In 85 percent of girls with Rett syndrome, the culprit is a faulty gene coding for methyl CpG-binding protein 2, (MeCP2), critical for nerve cell maturation. A deficit in MeCP2 stops neurons from growing spines, the branch-like projections needed for cell-to-cell communication.
Recent genetic studies have shown that increasing MeCP2 expression in mice led neurons to grow new spines, indicating that the disease could be reversible. Increased IGF-1 seems to make up for the lack of MeCP2.
Daily injections of the insulin-like growth factor IGF-1 extended the life spans of infant Rett syndrome mice, improved their motor function and breathing patterns and reduced irregularities in their heart rates. In addition, their brains had more nerve-cell spines.
IGF-1 affects almost every cell in the human body, especially in muscle, cartilage, bone, liver, kidney, nerves, skin and lungs. In addition to its insulin-like effects, IGF-1 also regulates cell growth and development in nerve cells.
"This is the first realistic way for a drug-like molecule injected into the bloodstream to relieve Rett syndrome symptoms," said Whitehead member Rudolf Jaenisch, whose lab participated in the research.

ScienceDaily